Ilona Steigerwald
Overview
Explore the profile of Ilona Steigerwald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleykamp B, Dworkin R, Turk D, Bhagwagar Z, Cowan P, Eccleston C, et al.
Pain
. 2021 Sep;
163(6):1006-1018.
PMID: 34510135
Chronic pain clinical trials have historically assessed benefit and risk outcomes separately. However, a growing body of research suggests that a composite metric that accounts for benefit and risk in...
2.
Gewandter J, Dworkin R, Turk D, Farrar J, Fillingim R, Gilron I, et al.
Pain Rep
. 2021 May;
6(1):e895.
PMID: 33981929
Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive...
3.
Smith S, Dworkin R, Turk D, McDermott M, Eccleston C, Farrar J, et al.
Pain
. 2020 Jun;
161(11):2446-2461.
PMID: 32520773
Interpreting randomized clinical trials (RCTs) is crucial to making decisions regarding the use of analgesic treatments in clinical practice. In this article, we report on an Initiative on Methods, Measurement,...
4.
5.
Baron R, Jansen J, Binder A, Pombo-Suarez M, Kennes L, Muller M, et al.
Pain Pract
. 2015 Nov;
16(5):600-19.
PMID: 26554630
Objective: To evaluate tolerability, safety, and quality-of-life outcomes in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic component receiving tapentadol PR vs. oxycodone/naloxone PR. Methods: Eligible patients...
6.
Baron R, Likar R, Martin-Mola E, Blanco F, Kennes L, Muller M, et al.
Pain Pract
. 2015 Jun;
16(5):580-99.
PMID: 26095455
Objective: To evaluate the effectiveness of tapentadol prolonged release (PR) vs. oxycodone/naloxone PR in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic pain component. Methods: Eligible patients...
7.
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy
Elling C, Galic M, Steigerwald I
Lancet Neurol
. 2015 Jun;
14(7):684-5.
PMID: 26067117
No abstract available.
8.
Eichenbaum G, Gohler K, Etropolski M, Steigerwald I, Pergolizzi J, Kim M, et al.
J Opioid Manag
. 2015 May;
11(3):211-27.
PMID: 25985806
Objectives: Opioid-induced androgen deficiency (OPIAD) affects patients treated with opioid analgesics. The norepinephrine reuptake inhibitor (NRI) and µ-opioid receptor (MOR) agonist activities of tapentadol may result in tapentadol having less...
9.
Gewandter J, Dworkin R, Turk D, Farrar J, Fillingim R, Gilron I, et al.
Pain
. 2015 Apr;
156(7):1184-1197.
PMID: 25887465
Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive...
10.
Sabatowski R, Scharnagel R, Gyllensvard A, Steigerwald I
Pain Ther
. 2014 Aug;
3(1):17-29.
PMID: 25135385
Introduction: Strong centrally acting analgesics, including tapentadol prolonged release (PR), have demonstrated efficacy for the management of non-malignant, chronic pain. Maintaining patient independence, including the ability to drive safely, is...